Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Agile Therapeutics
Comparative evaluation of AG200-15 versus OC with regard to safety, contraceptive efficacy, cycle control (bleeding pattern), subject compliance and serum concentrations of EE and LNG. To evaluate TCDS wearability (including adhesion).
Age
17–40
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Healthy females
17(in states where the legal age of consent to receive contraceptives is 17)-40 years
Regular, consistent menstrual cycles between 25 and 35 days
Sexually active women requesting birth control
In good general health, confirmed by medical history, physical (including gynecologic) examination and screening laboratory values
You may not be if
Known or suspected pregnancy;
Lactating women
Significant skin reaction to transdermal preparations or sensitivity to surgical / medical tape
Any disease that may worsen under hormonal treatment (cardiovascular, liver, metabolic)
Use of other contraceptive methods than study medication
Clareo Health | Study to Evaluate the Contraceptive Efficacy/Safety of a Low Dose EE/LNG Transdermal Contraceptive Delivery System
